Trop2在实体肿瘤中的临床研究进展  

Progress of Clinical Research on Trop2 in Solid Tumors

作　　者：张颖[1] 刘月平[1] ZHANG Ying;LIU Yueping(Department of Pathology,The Fourth Hospital of Hebei Medical University/Hebei Cancer Hospital,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院病理科,石家庄050011

出　　处：《肿瘤防治研究》2025年第1期79-86,共8页Cancer Research on Prevention and Treatment

摘　　要：滋养层细胞表面抗原2(Trop2)是一种在正常组织中几乎不表达而在恶性实体肿瘤中高度表达的糖蛋白,且与其不良预后显著相关。目前,临床开发了多种针对Trop2的靶向疗法,例如抗Trop2抗体和靶向Trop2的抗体偶联药物(ADC),一些已经被批准或正在临床试验中用于癌症治疗。本文对Trop2的基因结构、作用机制及其在实体肿瘤中的临床研究和药物研发等方面进行阐述,为临床开发更加安全有效的针对Trop2的靶向药物提供参考。Trophoblast cell surface antigen 2(Trop2)is a glycoprotein that is barely expressed in normal tissues but highly expressed in malignant tumors;it is remarkably associated with poor prognosis.Various targeted therapeutics against Trop2,such as anti-Trop2 antibodies and antibody-drug conjugate drugs targeting Trop2,have been developed,and some therapeutics have been approved or are in clinical trials for cancer treatment.In this review,we comprehensively discuss the gene structure,mechanism of action,clinical research,drug development,and other aspects of Trop2 to provide references for the clinical development of effective and safe Trop2-targeting drugs.

关 键 词：Trop2 癌症 机制 结构 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]